Blue Water Acquisition Corp

Blue Water Acquisition — Clarus Therapeutics — SPAC Merger (April 2021)

29 slides from Blue Water Acquisition's SPAC merger presentation, Apr 27, 2021

  1. Slide 1: Corporate Presentation April 2021

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 1 CORPORATE PRESENTATION APRIL 2021 INNOVATING FOR BETTER HEALTH

  2. Slide 2: Disclaimer

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 2 DISCLAIMER This presentation (“Presentation”) is for informational purposes only and is being furnished solely for the purpose

  3. Slide 3: Disclaimer (Cont'd)

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 3 DISCLAIMER (CONT’D) This Presentation does not purport to summarize all of the conditions, risks and other attributes of an in

  4. Slide 4: Clarus Leadership Team

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 4 ROBERT DUDLEY, PH.D President & CEO • Over 30 years experience in TRT field • Clarus co - founder • Extensive R&D experience a

  5. Slide 5: Clarus Leadership Team (cont.)

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 5 FRANK JAEGER, MA, MBA Chief Commercial Officer • Significant Medical Affairs experience • Multiple therapeutic area experience

  6. Slide 6: Blue Water Leadership Team and Board

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 6 • 25+ years of experience in healthcare • Founded or led 8 healthcare and pharmaceutical companies (i.e. Innovative Biosensors

  7. Slide 7: Investment Thesis

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 7 7 1 2 5 3 4 JATENZO is an FDA approved, first in class and only oral testosterone replacement therapy (“TRT”) of its kind to c

  8. Slide 8: The JATENZO Opportunity

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 8 THE JATENZO OPPORTUNITY

  9. Slide 9: Hypogonadism Overview

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 9 9 HYPOGONADISM OVERVIEW TESTOSTERONE DEFICIENCY IN MEN (HYPOGONADISM) IS A LARGE AND ATT RACTIVE MARKET OPPORTUNITY Male Hypog

  10. Slide 10: Pre-JATENZO Treatment Landscape

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 10 2014 2010 2003 Earlier TIMELINE OF SELECT TRT FDA APPROVALS 1995 1996 1997 1998 1999 2000 2001 2002 2015 2016 2017 2018 2019

  11. Slide 11: Importance of an Oral T Option

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 11 11 Current Non - oral Treatments Pose Administration Challenges The Cycle of Discontinuation More than 95,000 men change TRTs

  12. Slide 12: The JATENZO Opportunity: First Oral T of Its Kind

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 12 12 THE JATENZO OPPORTUNITY FIRST ORAL T OF ITS KIND APPROVED BY FDA – A LONG - AWAITED ADVANC E! CONVENIENT • Easy - to - swa

  13. Slide 13: JATENZO Product Differentiators

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 13 13 JATENZO PRODUCT DIFFERENTIATORS A SAFE ORAL WITHOUT LIVER TOXICITY ADDRESSES COMMON CONCERNS SEE N WITH INJECTIONS AND GEL

  14. Slide 14: Symptom Improvement

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 14 14 SYMPTOM IMPROVEMENT JATENZO INCREASES FREE TESTOSTERONE AND IMPROVES CLASSIC SIGNS A ND SYMPTOMS ASSOCIATED WITH HYPOGONAD

  15. Slide 15: JATENZO Safety Profile Consistent with TRT Class

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 15 Adverse Reactions ≥ 2% in 4 - Month Pivotal Trial of JATENZO JATENZO WAS SHOWN TO BE SAFE AND WELL - TOLERATED JATENZO SAFETY

  16. Slide 16: Health Care Providers and Patients Like JATENZO

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 16 “All of our TRT patients ask about different options. This is amazing. Finally.” “This is an innovative game changer, and thi

  17. Slide 17: TRT Market Performance in 2020

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 17 200,000 300,000 400,000 500,000 600,000 700,000 800,000 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Jun-19 Jul-19 Aug-19 Sep-19 Oct-19

  18. Slide 18: Focused Targeting

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 18 FOCUSED TARGETING CLARUS IS ENGAGING THE KEY TRT HCPS AND THE PATIENTS THEY TREAT Endocrinologists, Urologists, Primary Care

  19. Slide 19: Patient Support and Savings

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 19 PATIENT SUPPORT AND SAVINGS MOST COMMERCIAL COVERED PATIENTS WILL PAY $0 FOR THEIR PRESCRIPTION 19 19 TRT Market (Dec. 2020)

  20. Slide 20: Commercial Access – Market Comparison

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 20 fgfg COMMERCIAL ACCESS – MARKET COMPARISON JATENZO HAS COMPETITIVE COVERAGE THROUGHOUT 2021 20 0.00% 10.00% 20.00% 30.00% 40.

  21. Slide 21: JATENZO Has Consistently Grown Since Launch

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 21 21 2020 DEMAND SALES JATENZO HAS CONSISTENTLY GROWN SINCE LAUNCH DESPITE THE PANDEMIC AND COMMERCIAL PAYOR COVERAGE JATENZO T

  22. Slide 22: Empower the Patient: DTC and Spokesperson

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 22 EMPOWER THE PATIENT: DTC AND SPOKESPERSON 22 DTC Spokesperson • Launch Date: Q4/2021 • Launch Date: Q4/2021 • In Active Negot

  23. Slide 23: Expanding the Sales Force

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 23 EXPANDING THE SALES FORCE CREATES THE NATIONAL FOOTPRINT TO DELIVER ON BRAND STRATEGIES – MAXIMIZING SALES IMPACT • Sales For

  24. Slide 24: Potential Growth Areas

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 24 POTENTIAL GROWTH AREAS 24 • JATENZO out - licensing opportunities to recognize incremental and ongoing revenue with: • Europe

  25. Slide 25: Expansion Opportunities for JATENZO

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 25 EXPANSION OPPORTUNITIES FOR JATENZO 25 2021 2022 Product Company Indication Q1’21 Q2’21 Q3’21 Q4’21 Q1’22 Q2’22 Q3’22 Q4’22 J

  26. Slide 26: Transaction Summary

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 26 Transaction Summary

  27. Slide 27: Transaction Summary: Clarus + Blue Water

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 27 TRANSACTION SUMMARY 27 1. Exact amount dependent on final Investment amounts and redemptions at de - SPAC. • Business Combina

  28. Slide 28: Pro Forma Equity Ownership

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 28 28 Source: Company internal data 1. The amounts from the various sources of cash may change based on (i) the amount of Public

  29. Slide 29: Key Takeaways

    Clarus Therapeutics Confidential & Proprietary Information: Internal Use Only – Do Not Copy or Distribute / Contains Draft Propo sals Subject to Internal Review and Change 29 2 9 Right Team Highly relevant TRT experience with a track record of success Attractive Opportunity A high - growth category

Clarus Therapeutics — SPAC Merger (April 2021) on 6ix